You are here: Controversies / David Janowsky: Cholinergic muscarinic mechanisms in depression and mania
Thursday, 19.09.2019

David Janowsky: Cholinergic muscarinic mechanisms in depression and mania


         Dr. Thomas Ban recently published on a portion of his 1974 book in which he discussed the role of central cholinergic mechanisms in depression (Ban 1974). He has kindly invited me to comment on what has happened with respect to this topic in the 45 years since he published his comments. The following outlines, in condensed form and in approximate chronological order, a selective update of scientific progress in this area. The studies reviewed focus primarily on muscarinic effects, with nicotinic effects to be described at a later date. Much described here is taken from two recent articles (Van Enkhuizen, Janowsky, Olivier et al. 2015; Dulawa and Janowsky 2019) which discuss the above topic in greater depth.


1.      1889-1968: Early observations of acetylcholinesterase inhibitor and cholinergic agonist effects


         In 1889 E.F. Willoughby reported in the Lancet that the cholinergic agonist pilocarpine antagonized mania. Sixty-one years later Rowntree, Nevin and Wilson (1950) studied the acetylcholinesterase inhibitor diisoflurophosphonate (DFP) and observed antimanic and mood depressing effects in manics, as well as increases in depression in depressed patients and normals. Rowntree’s group also observed that some subjects exhibited psychotic symptoms. Subsequent studies of the effects of acetylcholinesterase inhibitor insecticides and nerve agents by Gershon and Shaw (1961) and Bowers, Goodman and Sim (1964) also demonstrated that these agents caused depression and anxiety. Consistent with these findings, preclinical studies by Domino and Olds (1968) demonstrated that cholinergic agents antagonized self-stimulation activity in rats. These findings are consistent with the observations of Helmut Selbach (1961), as described by Dr. Ban (1974), in which trophotropic (i.e., parasympathetic) predominance over ergotropic (i.e., sympathetic) influences were postulated to occur in depression and the anticholinergic effects of imipramine would shift mood to an ergotropic predominance thus alleviating depression.


2. 1972-1974: The adrenergic cholinergic balance hypothesis of mood disorders was proposed and explored


         The adrenergic-cholinergic balance hypothesis of mood disorders, in which an imbalance of too much acetylcholine activity relative to too little adrenergic (and/or dopaminergic) activity is thought to cause depression, and mania is caused by the converse was proposed by Janowsky, El-Yousef, Davis and Sekerke  (1972). This hypothesis was based largely on observations demonstrating that infusions of the short-acting and reversible acetylcholinesterase inhibitor, physostigmine, rapidly caused depression and anergia in patients with major depression and in depressed bipolar patients; it also dramatically reversed manic symptoms in patients who were in a manic state (Janowsky, El-Yousef, Davis and Sekerke 1973; Janowsky, El-Yousef and Davis 1974). Furthermore, a combination of marijuana and physostigmine caused profound depression in two normal volunteers (El Yousef, Janowsky, Davis et al. 1973); this was consistent with a rodent toxicity study demonstrating synergism between physostigmine and tetrahydrocannabinol (Rosenblatt, Janowsky, Davis et al. 1972). In addition, and consistent with the adrenergic cholinergic balance hypothesis, the dopamine/norepinephrine releasing psychostimulant methylphenidate antagonized physostigmine-induced lethargy and depression in patients. Conversely, physostigmine antagonized methylphenidate-induced psychostimulation, talkativeness and euphoria (Janowsky, El-Yousef and Davis 1973); these findings were augmented by experiments in rats in which physostigmine antagonized stereotyped gnawing behavior (Janowsky, El-Yousef and Davis 1979; Fibiger, Lynch and Cooper 1971).


3. 1973-1984: Follow-up studies of cholinergic agents causing depression and antagonizing mania


         Acetylcholine agonists, including pilocarpine, oxotremorine and arecoline (Carroll, Frazer, Schless and Mendels 1973; Davis, Berger, Hollister and Defraites 1978; Davis, Hollander, Davidson et al. 1987;) and acetylcholine precursors, including lecithin, deanol and choline (Tamminga, Smith, Change et al. 1976; Bajada 1982; Growden, Hirsch, Wurtman and Wiener 1977; Casey 1979), induced anxiety and depression in depressed and bipolar patients and antagonized mania in manics (Davis Berger, Hollister and Defraites 1978; Carroll, Frazer, Schless and Mendels 1973). In addition, exaggerated increases in depression were noted in patients suffering from depression or a history of depression (Janowsky, Risch, Parker et al. 1980) in contrast to more muted effects in subjects without a history of depression, findings suggesting cholinergic supersensitivity in patients with a history of a mood disorder.


4. 1973-1986: Mood depressant, cardiovascular and neuroendocrine effects of cholinomimetic drugs are due to increases in muscarinic activity and to central nervous system effects


         Depressant (anergy, sadness, negative thoughts), neuroendocrine (increases in beta endorphin, ACTH, epinephrine, cortisol), sleep (REM sleep changes) and cardiovascular changes (increased pulse rate and blood pressure) caused by cholinergic drugs appear to be centrally mediated. They occur when centrally acting physostigmine or arecoline were given, whereas neostigmine, a peripherally acting acetylcholinesterase inhibitor which does not enter the brain, did not cause these effects. The above effects also were antagonized by the centrally acting anti-muscarinic agent scopolamine but not by the non-centrally acting anticholinergic agent methscopolamine, again suggesting a muscarinic centrally mediated effect (Janowsky, El-Yousef and Davis 1974; Janowsky, Risch, Kennedy et al. 1986; Krieg and Berger 1986; Sitaram, Jones, Dube et al. 1983; Sitaram, Nurnberger, Gershon and Gillin 1983).


5. 1978—2004: Cholinomimetic Drugs mimic the effects of depression on sleep parameters


         Sleep parameters observed in depressed patients (i.e., shortened REM latency, increased REM density, increased REM activity, etc.) are mimicked by acetylcholinesterase inhibitors and acetylcholine receptor agonists in normals and these effects are exaggerated in mood disorder patients and their relatives, showing concordance in twin studies (Gillin, Sutton, Ruiz et al. 1991; Berger, Lund, Bronisch and von Zerssen 1983; Berger, Riemann, Hochli and Spiegel 1989; Berkowitz, Sutton, Janowsky et al. 1990; Lauriello, Kenny, Sutton et al. 1994; Sitaram, Dube, Keshavan et al. 1987; Rao, Lutchmansingh and Poland 1999; Sitaram et al 1982; Laurer, Modell, Schreiber et al. 2004; Sitaram, Nurnberger and Gershon1980).


6. 1981-2006: Cholinomimetic drugs mimic the endocrine changes occurring in depression


         Endocrine markers occurring in depression (increased ACTH, cortisol, beta endorphin, epinephrine and dexamethasone non-suppression) are mimicked by administration of cholinomimetic agents, including the acetylcholinesterase inhibitor, physostigmine and the acetylcholine agonist arecoline. Furthermore, beta-endorphin, growth hormone and ACTH increases are exaggerated in affective disorder patients (Rubin, Abbasi, Rhodes and Czambej 2003; Rubin, Rhodes, Miller et al. 2006; Risch, Janowsky and Gillin 1983; Risch, Janowsky, Mott et al.1985; Doerr and Berger 1983; O’Keane, O’Flinn, Lucey and Dinan 1992; Stoll, Sachs, Cohen et al. 1996; Davis and Davis1980).


7. 1996-2000: Cholinergic effects on pupillary constriction are exaggerated in depressives and muted in manics


         Pupillary reactivity to the muscarinic agonist pilocarpine is increased in depressed individuals and is sub-sensitive in manic patients (Sokolski and Dement 1996, 2000). These findings are consistent with the adrenergic-cholinergic balance hypothesis.


8. 1984-present: A number of studies suggest that the behavioral manifestations of stress are mediated by an increase in central acetylcholine


         In parallel with studies of the relationship of acetylcholine to depression are studies of the relationship of stress to cholinergic mechanisms as reviewed by Janowsky and Risch (1984) and Dagyte, Den Boer and Trentani (2011). These typical stress effects include the increase in blood pressure and pulse rate, the release of cortisol, ACTH, epinephrine and beta endorphin and the inducing of anxiety and dysphoria. In addition, as reviewed in depth elsewhere (Janowsky and Risch 1984; Dagyte, Den Boer and Trentani 2011; Janowsky, Overstreet and Nurnberger 1994)), stress increases central acetylcholine levels and this increase is probably due to central effects of corticotropin releasing factor. In addition, Fernandes, Koth, Parfitt et al. (2018) found in mice that increasing cholinergic tone with physostigmine shortly before an application of stress increases the impact of the stress. These authors also found that stress related increases in acetylcholine led to depressive symptoms in rodents. Similarly, Gollan, Hongxin, Bruno et al. (2017) reported that basal forebrain mediated increases in brain CRF are associated with increased cholinergic tone and depression. Furthermore, Chen, Rada, Butzler et al. (2010) reported that corticotropin releasing factor in the nucleus accumbens shell induces depression, anxiety and anhedonia. Finally, Day, Kohl, Le Moal and Maccari (1998) found that corticotropin-releasing factor, administered centrally but not peripherally, stimulates hippocampal acetylcholine release.


9. 1993-present: Imaging studies in humans show changes in muscarinic and nicotinic cholinergic receptors


         Sophisticated imaging techniques demonstrate that the acetylcholine precursor choline is elevated in brains of depressed patients and decreases when the depression is treated with antidepressants (Charles, Lazeyras, Krishnan et al. 1993; Renshaw, Lafer, Babb et al. 1997). Also, muscarinic-2 and muscarinic-4 receptor binding is decreased in depressed patients. Depressive disorder patients also show lower Beta-2 nicotinic acetylcholine receptor activity compared to controls. Similarly, lower nicotinic Beta-2 receptors in bipolar patients were found. This lowered receptor binding has been postulated to be due to increased acetylcholine levels causing decreased (down regulated) receptor binding (Zavitsanou, Katsifis, Attner and Huang 2004; Zavitsanou, Katsifis, Yu and Huang 2005; Jeon, Gibbons and Dean 2013; Gibbons, Scarr, McLean et al. 2009; Gibbons, Jeon, Scarr and Dean 2016; Comings, Wu, Rostamkhani et al. 2002; Wang, Hinrichs, Stock et al. 2004; MacMaster and Kusumakar 2006; Riley and Renshaw, 2018; Cannon, Klaver, Gandhi et al. 2011; Hannestad, Cosgraove, DellaGloia et al. 2013; Saricicek, Esterlis, Maloney et al. 2012; Renshaw, Lafer, Babb et al. 1997; Cannon, Carson, Nugent et al. 2006; Jeon, Dean, Scarr and Gibbons 2015).


10. 2006-present. The centrally acting antimuscarinic anticholinergic agent scopolamine alleviates depression


         In 2006 investigators at the intramural program at NIMH discovered, using a double-blind cross over design, that the pan-muscarinic acetylcholine blocking agent, scopolamine (4 micrograms/ kg. IV), was effective in rapidly alleviating bipolar and unipolar depression symptoms (Furey and Drevets 2006). These results were replicated in a subsequent study (Drevets and Furey 2010). A second replication study (Park, Furey, Nugent et al. 2019), also done at the NIMH by the same group, was negative but utilized a sicker patient group. In a study performed in Iran using oral medications, scopolamine (1.0 mg PO) was found to augment the effectiveness of oral citalopram in depressed outpatients (Khajavi, Farokhnia, Modabbernia  et al. 2012).

         The major breakthrough studies showing rapidly occurring antidepressant activity for scopolamine (Furey and Drevets 2006) and for ketamine were published within months of each other in 2006, with both studies originating in the intramural program at NIMH and with an overlap of investigators occurring. The effectiveness of both drugs was similar and the experimental design was also very similar. For a number of reasons, possibly in part based on decisions concerning marketing emphasis, drug company support of studies, patent issues and the role of fads in scientific exploration, ketamine has subsequently received much more media attention and many more clinical studies and preclinical studies have evaluated ketamine than have evaluated scopolamine as an antidepressant. However, preclinical studies of scopolamine alleviating depression-like behaviors in rodents have been continuing at a rapid pace and the results virtually all demonstrate that scopolamine is an effective antidepressant agent.


11. 2011-present: Specific areas of brain regulate central cholinergic depression like symptoms in rodents and scopolamine's antidepressant effects


         Increasing central acetylcholine in specific brain areas, including the ventral tegmental area, nucleus accumbens, hippocampus and medial prefrontal cortex in mice and rats, was found to cause depression-like behaviors. These behaviors were antagonized by scopolamine, by acetylcholine knockout techniques and by fluoxetine. Fluoxetine’s ability to increase acetylcholinesterase activity, i.e. to more effectively metabolize acetylcholine, was proposed as a reason for fluoxetine’s antidepressant effects (Small, Nunes, Hughley and Addy  2016; Addy, Nunes and Wickham 2015; Chau, Rada, Kim  et al. 2011; Navarria, Wohleb, Voleti et al. 2015; Mineur, Cahuzac, Mose et al. 2018; Chau, Rada, Kosloff et al. 2001; Padua-Reis, Aquino, Olierira et al. 2017; Witkin, Overshiner, Li et al. 2014).


12. 2015-present: Scopolamine combined with certain other drugs showed increased antidepressant efficacy/synergy in animal models of depression


         Venlafaxin plus scopolamine and reboxetine plus scopolamine showed synergistic increased antidepressant effects, as did ketamine plus scopolamine and citalopram plus scopolamine. Similarly, scopolamine plus the II mGlu receptor antagonist LY341495 exerted synergistic antidepressant effects in rats and mice, thus suggesting therapeutic potential (Singh and Singh, 2015; Palucha-Poniewiera, Podkowa, Lenda and Pilc 2017; Petryshen, Lewis, Denney et al. 2016; Podkowa, Podkowa, Salat et al. 2016; Martin, Schober, Nikolayey et al. 2017).


13. 2011-present: A number of neurotransmitters and neuromodulators are necessary for scopolamine to exert antidepressant effects


         There is evidence from rat and mouse studies that other neurotransmitters and neuromodulators are necessary for scopolamine to exert its antidepressant effects. These include protein Kinase A (Dong, Zhou, Wei  et al. 2018), mTOR activation (Voleti, Navarria, Liu et al. 2013; Martin, Schober, Nikolayey et al. 2017; Liu, Banasr, Li N et al.  Terwilliger 2013), brain derived neurotrophic factor (Yu, Li, Zhou et al. 2018; Ghosal, Bange, Yue et al. 2018), monoaminergic neurotransmitters including norepinephrine (Palucha-Poniewiera, Podkowa, Lenda and Pilc 2017) and dopamine), GABA interneurons (Wohleb, Wu, Gerhard et al. 2016; Wohleb, Gerhard, Thomas and Duman 2017), mGlu7 receptor ligands (Podkowa, Podkowa, Salat et al. 2016; Podkowa, Pilc, Podkowa et al. 2018), Vesicular glutamate transporter 1, AMPAR (Yu, Li, Zhou et al. 2018; Yu, Li, Shen et al. 2018; Martin, Schober, Nikolayey et al. 2017) and voltage dependent calcium channels (Yu, Li, Zhou et al. 2018; Yu, Li, Shen et al. 2018; Yu, Lv, Shen et al. 2019). Thus, how muscarinic effects occur as they relate to downstream phenomena remains an area open for much further exploration, the results of which may give important clues as to the pathophysiology of mood disorders.


14. The cholinergic-nicotinic nervous system and affective disorders


         The role of nicotinic activity as it relates to affective disorders is not a major focus of this communication. Very few experiments have studied whether nicotine has antidepressant effects in non-smoking depressed patients (Salin-Pascual, Rosas, Jimenez-Genchi et al. 1996). Those that have done so have generally shown antidepressant effects. Stimulation of nicotinic receptors also leads to antidepressant and antianxiety effects in animal models of depression (Andreasen, Henningsen, Bate et al. 2011; Andreasen, Redrobe and Nielsen 2012; Picciotto, Lewis, van Schalkwyk and Mineur 2015; Mineur and Picciotto 2010; Mineur, Fote, Blakeman et al. 2016; Mineur, Mose, Blakeman et al. 2018; Biala, Pekala, Boguszewska-Czbara et al. 2017). For example, stimulation of alpha 7 nicotinic receptors causes antidepressant effects in animal models (Zhao, Julian, Pan et al. 2017) and when these receptors are blocked or knocked out, depression-like behaviors occur (Zhang, Liu and Zhou 2018). In addition, surprisingly few studies have explored potential interactions between muscarinic and nicotinic activity. As an exception He, Zhang, Wang et al. (2015) reported that muscarinic activation inhibits nicotinic activity in sympathetic neurons and in chromaffin cells. Given that both systems are cholinergic, studies of their interactions could yield important insights regarding pathophysiology and treatment possibilities.



Addy NA, Nunes EJ, Wickham RJ. Ventral tegmental area cholinergic mechanisms mediate behavioral responses in the forced swim test. Behav Brain Res. 2015;288:54-62.

Andreasen JT, Henningsen K, Bate S. Christiansen S, Wilborg O. Nicotine reverses anhedonic-like response and cognitive impairment in the rat chronic mild stress model of depression: comparison with sertraline. J Psychopharmacol. 2011;25:1134-41.

Andreasen JT, Redrobe JP, Nielsen EO. Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacy Biochem Behav. 2012;100:624-9.

Ban TA. Depression and the Tricyclic Antidepressants, Chapter 4, Depression, Montreal: Ronalds Federated; 1974;45-6.

Bajada S. A trial of choline chloride and physostigmine in Alzheimer’s dementia. In Alzheimer’s Disease: a report of progress. Edited by Corkin S, Davis K, Growden J. New York:  Raven Press; 1982. pp. 427-43.

Berger M, Lund R, Bronisch T, von Zerssen D. REM latency in neurotic and endogenous depression and the cholinergic REM induction test. Psychiatry Res. 1983;10:113-23.

Berger M, Riemann D, Hochli D, Spiegel R. The cholinergic rapid eye movement sleep induction test with RS-86. State or trait marker of depression? Arch Gen Psychiatry. 1989;46:421-8.

Berkowitz A, Sutton L, Janowsky DS, Gillin JC. Pilocarpine , an orally active muscarinic cholinergic agonist induces REM sleep and reduces delta sleep in normal volunteers. Psychiatry Res. 1990; 33:113-9.

Biala G, Pekala K, Boguszewska-Czbara, Michalac A, Kru Slomka M, Budzynska B.  Behavioral and biochemical interaction between nicotine and chronic unpredictable mild stress in mice.  Mol                Neurobiol. 2017;54 (2)904-921.

Bowers MB, Goodman E, Sim VM. Some behavioral changes in man following anticholinesterase administration. J Nerv Ment Dis. 1964;138:383-9.

Cannon DM, Carson RE, Nugent AC, Eckelman WC, Kiesewelter DO, Williams J, Rollis D, Drevets M, Gandhi S, Solono G, Drevets WC. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry. 2006;63:741-7.

Cannon DM, Klaver JK, Gandhi SK, Solono G, Peck SA , Erickson K, Akula N, Savitz J, Eckelman WC, Furey ML, Sahakian BJ, McMahon FJ, Drevets WC. Genetic variation in cholinergic muscarinic-2 receptor gene modulates M2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry. 2011;16:407-8.

Carroll BJ, Frazer A, Schless A, Mendels J. Cholinergic reversal of manic symptoms. Lancet 1973;428.

Casey DE. Mood alterations during deanol therapy. Psychopharmacology. 1979; 62:187-91.

Chau DT, Rada P, Kosloff RA. Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant effect of local M1 antagonist in the porsolt swim test. Neuroscience. 2001;104:791-8.

Chau DT, Rada PV, Kim K, Kosloff RA, Boebel BG. Fluoxetine alleviates behavioral depression while decreasing acetylcholine release in the nucleus accumbent shell. Neuropsychopharmacology. 2011;36:1729-37.

Charles HC, Lazeyras F, Krishnan IR, Boyko OB, Payne M, Moore D. Brain choline in depression: in vivo detection of potential pharmacodynamic effects of antidepressant therapy using hydrogen localized spectroscopy. Prog Neuropsychopharmacol Biol Psychiatry. 1993;18:1121-7.

Chen YW, Rada PV, Butzler BP, Leibowitz SF, Hoebel BG. Corticotropin-releasing factor in the nucleus accumbens shell induces swim depression, anxiety, and anhedonia along with changes in local dopamine/ acetylcholine balance. Neuroscience. 2010;206: 155-66.

Comings DE, Wu S, Rostamkhani M, McGue M, Iacono WG, MacMurray JF. Association of the muscarinic cholinergic 2 receptor ( CHRM2) gene with major depression in women. Am J Med Genet. 2002;114:527-9.

Dagyte G, Den Boer JA, Trentani A. The cholinergic system and depression. Behav Brain Res. 2010;221:574-82.

Davis KL, Berger PA, Hollister LE, Defraites E. Physostigmine in mania. Arch Gen Psychiatry. 1979; 35:119-22.

Davis BM, Davis KL. Cholinergic mechanisms and anterior pituitary hormone secretion. Biol Psychiatry. 1980; 15:303-10.

Davis KL, Hollander E, Davidson M, Davis BM, Mohs RC, Horvath TB. Induction of depression with oxotremorine in patients with Alzheimer’s disease. Am J Psychiatry. 1987;144:468-71.

Day JC, Kohl M, Le Moal M, Maccari S. Corticotropin-releasing factor administered centrally, but not peripherally stimulates hippocampal acetylcholine release. J Neurochem. 1998;71(2):622-629.

Doerr P, Berger M. Physostigmine-induced escape from dexamethasone suppression in normal adults. Biological Psychiatry. 1983;18:261-268.

Domino EF, Olds ME. Cholinergic inhibition of self-stimulation behavior. J. Pharm. Exp Therapeutics. 1968;164:202-211.

Dong J, Zhou Q, Wei Z, Yan S, Sun F, Cai X. Protein kinase A mediates scopolamine-induced mTOR activation and an antidepressant response. J Affect Disor. 2018; 227: 633-642.

Drevets WC, Furey ML. Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized placebo-controlled clinical trial. Biological Psychiatry. 2010; 67:432-438.

Dulawa SC, Janowsky DS. Cholinergic regulation of mood: from basic and clinical studies to emerging therapeutics. Mol. Psychiatry, 2019; 24(5):694-709.

El Yousef M, Janowsky DS, Davis JM, Rosenblatt J. Induction of severe depression in marijuana intoxicated individuals. Br J Addict. 1973;68:321-325.

Fernandes SS, Koth AP, Parfitt GM, Condeiro MF, Pelxoto CS, Soubhia A, Moreira FP, Wiener CD, Uses JP, Kozzobowski E, Barros D. Enhanced cholinergic tone during stress induces a depressive like state in mice. Behav Brain Res. 2018;347:17-25.

Fibiger HC, Lynch GS, Cooper HP. A biphasic action of central cholinergic stimulation on behavioral arousal in the rat. Psychopharmacologia (Berl). 1971;20:366-382.

Furey ML, Drevets WC. Antidepressant efficacy of the antimuscarinic drug scopolamine. Arch Gen Psychiatry. 2006;63:1121-1129.

Gershon S, Shaw FH. Psychiatric sequelae of chronic exposure to organophosphorus insecticides. Lancet. 1961;1:1371-1374.

Ghosal S, Bange, Yue W, Hare BD, Lepack AE, Gigente MJ, Dumar RS. Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine. Biol psychiatry. 2018;83:29-37.

Gibbons AS, Scarr E, McLean C, Sundram S, Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord. 2009;116(3):184-191.

Gibbons AS, Jeon WJ, Scarr E, Dean B. Changes in muscarinic M2 receptor levels in the cortex of subjects with bipolar disorder and major depressive disorder and in rats after treatment with mood stabilizers and antidepressants. Int J Neuropsychopharmacology. 2016;20:19(4):118.

Gillin JC, Sutton L, Ruiz C, Darko D, Golsham S, Risch SC, Janowsky D. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol Psychiatry. 1991;30(2):157-169.

Gillin JC, Sutton L, Ruiz C, Kelsoe J, Dupont RM, Darko D, Risch, Janowsky DS. The cholinergic rapid eye movement induction test with arecoline in depression. Arch Gen Psychiatry. 1991;48(3):264-270.

Gollan JK, Hongxin D, Bruno D, Nierenberg J, Nobrega JN, Grotte J, Pollock BG, Marmar CR, Teipel S, Csernansky JG, Pomara N. Basal forebrain mediated increase in brain CRF is associated with increased cholinergic tone and depression. Psychiatric Research. 2017; 264:76-81.

Growdon JH, Hirsch MJ, Wurtman RJ, Wiener W.  Oral choline  administration to patients with tardive dyskinesia.  N Engl J Med.  1977;297(10):524-527.

Hannestad JO, Cosgraove KP, DellaGloia NF, Perkins E, Bois F, Bhagwagar Z, Seibyl JP, McClure-Begley TD, Picciotto MR, Esterlis I. Changes in the cholinergic system between bipolar depression and euthymia as measured with [1231]51A single photon emission computed tomography. Biol. Psychiatry. 2013;74(10):768-776.

He LL, Zhang QF, Wang LC, Dai JX, Wang CH, Zheng LH, Zhou Z. Muscarinic inhibition of nicotinic transmission in rat sympathetic neurons and adrenal chromaffin cells. Philos Trans R Soc Lnd B Biol Sci. 2015;5:370

Janowsky DS, El-Yousef MK, Davis JM, Sekerke J. A cholinergic-adrenergic hypothesis of mania and depression. Lancet. 1972;2:632-635.

Janowsky DS, El-Yousef MK, Davis JM, Sekerke J. Parasympathetic suppression of manic symptoms by physostigmine. Arch Gen Psychiatry. 1973;28:542-547.

Janowsky DS, El-Yousef MK, Davis JM. Antagonistic effects of physostigmine and methylphenidate in man. American Journal of Psychiatry. 1973;130:1370-1376.

Janowsky DS, El-Yousef MK, Davis JM. Acetylcholine and depression. Psychosom Med. 1974;36:248-257.

Janowsky DS, El-Yousef MK, Davis JM. Cholinergic antagonism of methylphenidate- induced stereotyped behavior. Psychopharmacology 1979;60:237-240.

Janowsky DS, Risch C, Parker D. Huey L, Judd L. Increased vulnerability to cholinergic stimulation in affective-disorder patients (proceedings). Psychopharmacol Bull. 1980;16 (4):29-31.

Janowsky DS, Risch SC. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorder and stress. Drug Dev Res. 1984;4:125-142.

Janowsky DS, Risch SC, Kennedy B, Ziegler M, Huey L. Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release. Psychopharmacology. 1986;89:150-154.

Janowsky DS, Overstreet DH, Nurnberger JL Jr. Is cholinergic sensitivity a genetic marker for the affective disorders? Amer J. Med Genet. 1994;54(4):335-344.

Jeon WJ, Gibbons AS, Dean B. The use of a modified (3H) 4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2013;47:7-12.

Jeon WJ, Dean B, Scarr E, Gibbons A. The role of muscarinic receptors in the pathophysiology of mood disorders: a potential novel treatment. Current Neuropharmacology. 2015;13(6):739-749.

Khajavi D, Farokhnia M, Modabbernia A, Ashrafi M, Abbasi Sh, Tabrizi M, Akhondzaeh S. Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized double-blind, placebo-controlled study. J Clin Psychiatry. 2012;73(11):1428-33.

Krieg JC, Berger M. Treatment of mania with the cholinomimetic agent RS-86. Br J Psychiatry. 1986;148:613.

Laurer CJ, Modell S, Schreiber W, Krieg JC, Holsboer F. Prediction of the development of a first major depressive episode with a rapid eye movement sleep induction test using the cholinergic agonist RS 86. J Clin Psychopharmacol. 2004; 24(3):356-357.

Lauriello J, Kenny WM, Sutton L, Golshan S, Ruiz C, Kelso J, Rapaport M, Gillin JC. The cholinergic REM sleep induction test with pilocarpine in mildly depressed patients and normal controls. Biol Psychiatry 1993, 1;33(1):33-9.

Liu RJ, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74(10):742-9.

MacMaster FP, Kusumakar V. Choline in pediatric depression. McGill J Med. 2006; 9 (1): 24-27.

Martin AE, Schober DA, Nikolayey A, Tolstikov VV, Andersen WH, Higgs RE, Kuo MS, Laksmanan P, Catlow JT, Li X, Felder CC, Witkin JM. Further evaluation of mechanisms associated with the antidepressant like signature of scopolamine in mice. CNS Neurol Disord Drug Targets. 2017;16(4):492-500.

Mineur YS, Picciotto MR. Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci. 2010;31(12):580-586.

Mineur YS, Obayemi A, Wigestrand MB, Fote GM, Calarco CA, Li AM, Picciotto MR. Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety and depression-like behavior. 2013. Proc Natl Acad Sci USA. 2013;110:(9):3573-3578.

Mineur YS, Fote GM, Blakeman S, Cahuza EL, Newbold SA, Picciotto MR. Multiple acetylcholine receptor subtypes in the mouse amygdala regulate affective behaviors and response to social stress. Neuropsychopharmacology. 2016; 41(6):1579-1587.

Mineur YS, Cahuzac EL, Mose TN, Bentham NP, Plantessya ME, Thompson DC, Picciotto MR. Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety and depression related behaviors in mice. Neuropsychopharmacology. 2018;43:(10):2118-2125.

Mineur YS, Mose TN, Blakeman S, Picciotto MR. Hippocampal α7 nicotinic ACh receptors contribute to modulation of depression-like behaviour in C57BL/6J mice. Br J Pharmacol. 2018;175(11):1903-1914.

Navarria A, Wohleb ES, Voleti B, Ota KT, Dutheil S, Lepack AE, Dwyer JM, Fuchikami M, Becker A, Drago F, Duman RS. Rapid antidepressant actions of scopolamine: role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptors. Neurobiol Dis. 2015;82:254-261.

Nurnberger JL Jr., Sitraram N, Gershon ES, Gillin JC. A twin study of cholinergic REM induction. Biol Psychiatry. 1983;18(10):1161-1173.

O’Keane V, O’Flinn K, Lucey J, Dinan TG. Pyridostigmine-induced growth hormone responses in healthy and depressed subjects: evidence for cholinergic supersensitivity in depression. Psychol Med. 1992;22(1):55-60.

Olds ME, Domino EF. Comparison of muscarinic and nicotinic cholinergic agonists on selfstimulating behavior. J Pharm Exp. Therapeutics. 1969;166 (2):189-204.

Padua-Reis M. Aquino NS, Olierira VEM, Szawka RE, Prado VF. Reduced Vesicular Acetylcholine Transporter favors antidepressant behaviors and modulates serotonin and dopamine in female mouse brain. Behave Brain Res. 2017;330:127-132.

Palucha-Poniewiera A, Podkowa K, Lenda T, Pilc A. The involvement of monoaminergic neurotransmission in the antidepressant like effect of scopolamine in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry. 2017;79(Pt B):155-161.

Park L, Furey, Nugent AC, Farmer C, Ellis J, Szczepanik J, Lener MS, Karate CA. Neurophysiological changes associated with antidepressant response to ketamine not observed in a negative trial of scopolamine in major depressive disorder. Int J Neuropsychopharmacol. 2019;22(1):10-18.

Petryshen TL, Lewis MC, Denney KA, Garza JC, Fava M. Antidepressant-like effect of low dose ketamine and scopolamine co-treatment in mice. Neuro. Lett. 2016;4620:70-73.

Picciotto MR, Lewis AS, van Schalkwyk GI, Mineur YS. Mood and anxiety regulation by nicotinic acetylcholine receptors: A potential pathway to modulate aggression and related behavioral states. Neuropharmacology. 2015;96(Pt B):235-43.

Podkowa K, Podkowa A, Salat K, Lenda T, Pilc A, Palucha-Poniewiera A. Antidepressant-like effects of scopolamine in mice are enhanced by the group II mGlu receptor antagonist LY341495. Neuropharmacology. 2016;111:169-179.

Podkowa K, Pochwat B, Branski P, Pilc A. Group II mGlu receptor antagonist LY 341495 enhances the antidepressant-like effects of ketamine in the forced swim test in rats. Psychopharmacology (Berl). 2016; 233:2901-2914.

Podkowa K, Pilc A, Podkowa A, Sałat K, Marciniak M, Pałucha-Poniewiera A.The potential antidepressant action of adverse effects profiles scopolamine co-adminstered with the mGlu 7 receptor allosteric agonist AMN082 in mice. Neuropharmacology. 2018; 141:214-222.

Poland RE, McCracken JT, Lutchmansingh P, Lesser IM, Tondo L, Edwards C, Boone KB, Lin KM. Differential response of rapid eye movement sleep to cholinergic blockade by scopolamine in currently depressed, remitted and normal control subjects. Biological Psychiatry. 1997;41(9)929-938.

Pytka K, Dziubina A, Mlynniec K, Dziedziczak A, Zmudzka E, Furgala A, Olczyk A, Sapa J, Filipek B. The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. Pharmacol Rep. 2016;68(2):443-450.

Rao U, Lutchmansingh P, Poland RE.  Age related effects of scopolamine on REM sleep regulation in in normal control subjects: relationship to sleep abnormalities in depression.                         Neuropsychopharmacology.  1999; 21(6):723-730.

Renshaw PF, Lafer B, Babb SM, Fava M, Still AL, Christensen JD, Yurgelun-Todd DA, Bonello CM, Pillay SS, Rothchild AJ, Nierenburg AA, Rosenbaum F, Cohen BM. Basal Ganglia choline levels in depression and response to fluoxetine treatment: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry. 1997;41:837-843.

Riley CA, Renshaw PF. Brain choline in major depression: A review of the literature.  Psychiatry Res Neuroimaging. 2018;271:142-153.

Risch SC, Janowsky DS, Gillin JC. Muscarinic supersensitivity of anterior pituitary ACTH and B-endorphin release in major depressive illness. Peptides. 1983;4(5)789-792.

Risch SC, Janowsky DS, Mott MA, Gillin JC, Kalir HH, Huey L, Ziegler M, Kennedy B, Turken A. Central and peripheral cholinesterase inhibition: effects on anterior pituitary and sympathomimetic function. Psychoneuroendocrinolgy. 1985;11(2):221-230.

Rosenblatt JE, Janowsky DS, Davis JM, El-Yousef MK. The augmentation of physostigmine toxicity in the rat by delta 9 tetrahydrocannabinol. Res Com Chem Path Pharm. 1972;3:478-482.

Rowntree DW, Nevin S, Wilson A. The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis. J Neurol. Neurosurg, Psychiat. 1950; 13:47-62.

Rubin RT, Abbasi SA, Rhodes ME, Czambej RK. Growth hormone responses to low dose physostigmine administration: functional sex differences (sexual diergism) between major depressive and matched controls. Psychol Med. 2003;33(4):655-665.

Rubin RT, Rhodes ME, Miller TH, Jakab RL, Czambel RK. Sequence of pituitary-adrenal cortical hormone responses to low-dose physostigmine administration in young adult women and men. Life Sci. 2006; 79:2260-2268.

Salin-Pascual RJ, Rosas M, Jimenez-Genchi A, Rivera-Meza BL, Delgado-Parra V. Antidepressant Effects of transdermal nicotine patches in non-smoking patients with major depression. J Clin Psychiatry. 1996;57(9):387-389.

Saricicek A, Esterlis I, Maloney KH, Mineur YS, Ruf BM, Muralidharan A, Chen JI, Cosgrove KP, Kerestes R, Ghose S, Tamminga CA, Pittman B, Bois F, Tamagnan G, Seibyl J, PIcciotto MR, Staley JK, Bhagwagar Z. Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder. Am J Psychiatry. 2012;169(8):851-859.

Selbach H. Ueber die vegetative Dynamic in der psychiatrischen   Pharmakotherapie.  Dtsh Med J. 1961; 12:511-517.

Shin JH, Adrover MF, Wess J, Alvarez VA. Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens. Proc Natl Acad Sci U S A. 2015;112(26):8124-9.

Singh P, Singh TG. Modulation of muscarinic system of serotonin-norepinephrine reuptake inhibitor antidepressant attenuates depression in mice. Indian J Pharmacol. 2015;47(4):388-393.

Sitaram N, Nurnberger J, Gershon ES. Faster cholinergic REM sleep induction in euthymic patients with primary affective illness. Science. 1980 Apr 11;208(4440):200-2.

Sitaram N, Jones D, Dube S, Keshavan M, Davies A, Reynal P. The association of supersensitive cholinergic REM-induction and affective illness within pedigrees. J Psychiatric Res. 1983;21:487-497.

Sitaram N, Nurnberger J, Gershon ES, Gillin JC. Cholinergic regulation of mood and REM sleep: a potential model and marker for vulnerability to depression. Am J Psychiatry. 1983;139:571-576.

Sitaram N, Dube S, Keshavan M, Davies A, Reynal P. The association of supersensitive cholinergic REM-induction and affective illness within pedigrees. J Psychiatr Res. 1987;21(4):487-97.

Small KM, Nunes E, Hughley S, Addy NA. Ventral tegemental area muscarinic receptors modulate depression and anxiety-related behaviors in rats. Neurosci Lett. 2016;616:80-85.

Sokolski KN, DeMet EM. Increased pupillary sensitivity to pilocarpine in depression. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:253-2

Sokolski KN, DeMet EM. Cholinergic sensitivity predicts severity of mania. Psychiatry Res. 2000;95(3):195-200.

Stoll AL, Sachs GS, Cohen BM Lafer B, Christensen JD, Renshaw PF. Choline in the treatment of rapid-cycling bipolar disorder : clinical and neurochemical findings in lithium treated patients.  Biol Psychiatry.  1996;40(5):382-388.

Tamminga C, Smith RC, Change S, Haraszti JS, Davis JM. Depression associated with oral choline. Lancet. 1976;2:905.

van Enkhuizen J, Milienne-Petiot M, Geyer MA, Young JW. Modeling bipolar disorder in mice by increasing acetylcholine or dopamine: chronic lithium treats most but not all features. Psychopharmacology (Berl). 2015;232:3455-3467.

van Enkhuizen J, Janowsky DS, Olivier B, Minassian A, Perry W, Young JW, Geyer MA. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited. European Journal of Pharmacology. 2015;753:114-126.

Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, Sanacora G, Eid T, Aghajanian G, Duman RS.  Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses.  Biol Psychiatry. 2013;74(10):742-9.

Wang JC, Hinrichs AL, Stock H, Budde J, Allen R, Bertelsen S, Kwon JM, Wu W, Dick DM, Rice J, Jones K, Nurnberger JL Jr., Tischfield J, Porjesz B, Edenberg HJ, Hesselbrock V, Crowe R, Schuckit M, Begleiter H, Reich T, Goate AM, Bierut LJ. Evidence of common and specific genetic effects: association of the muscarinic acetylcholine receptor M2 (CHRM2) gene with alcohol dependence and major depressive syndrome. Hum Mol Genet. 2004;13:1903-1911.

Willoughby EF. Pilocarpine in Threatening Mania. Lanet. 1889.

Witkin JM, Overshiner C, Li X, Catlow JT, Wishart GN, Schober DA, Heinz BA, Nikolayey A, Tolstikov VV, Anderson WH, Higgs RE, Kuo MS, Felder CC. M1 and m2 muscarinic receptor subtypes regulate antidepressant-like effects of the rapidly acting antidepressant scopolamine. J Pharmacol Exp Ther. 2014;351:448-458.

Wohleb ES, Wu M, Gerhard DM, Taylor SR, Picciotto MR, Duman RS. GABA interneurons mediate the rapid antidepressant like effects of scopolamine. Journal Clinical Investigation 2016:126:1282-94.

Wohleb ES, Gerhard D, Thomas A, Duman RS. Molecular and cellular mechanisms of rapidacting antidepressants ketamine and scopolamine. Curr Neuropharmacol 2017;15:11-26.

Yu H, Li M, Zhou D, Lv D, Liao Q, Lu Z, Shen M, Wang Z, Li M, Xiao X, Zhang Y, Wang C. Vesicular glutamate transporter 1 (VGLUT1)-mediated glutamate release and membrane GluA1 activation is involved in the rapid antidepressant-like effects of scopolamine in mice. Neuropharmacology 2018;131:209-222.

Yu H, Li M, Shen X, Lv D, Sun X, Wang J, Gu X, Hu J, Wang C. The Requirement of L-Type Voltage-Dependent Calcium Channel (L-VDCC) in the Rapid-Acting Antidepressant-Like Effects of Scopolamine in Mice. Int J. Neuropsychopharmacol. 2018;21(2)174-186.

Yu H, Lv D, Shen M, Zhang Y, Zhou D, Chen Z, Wang C. BDNF mediates the protective effects of scopolamine in reserpine-induced depression-like behaviors via up-regulation of 5-HTT and TPH1. Psychiatry Res. 2019;271:328-334.

Zavitsanou K, Katsifis A, Attner F, Huang XE. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology. 2004;29(3):619-625.

Zavitsanou K, Katsifis A, Yu Y, Huang XE. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull. 2005; 65(5):397-403.

Zhang C, Liu X, Zhou P. Cholinergic tone in ventral tegmental area: Functional organization and behavioral implications. Neurochem. Int. 2018;114:127-133.

Zhao D, Julian X, Pan L, Zhu W, Fu X, Guo L, Lu Q, Wang J. Pharmacologic activation of cholinergic alpha 7 nicotinic receptors mitigates depressive like behavior in a mouse model of chronic stress. J Neuroinflammation. 2017;14(1):234.


September 12, 2019